Insider Trading June 1, 2026 04:19 PM

Riskified Director Sells Shares Amid Mixed Performance and Analyst Support

SEC filings detail $1M+ transactions by director; company reports Q1 revenue beat despite EPS miss.

By Nina Shah RSKD

A recent SEC Form 4 filing disclosed that Shachar Erez, a director at Riskified Ltd. (NASDAQ:RSKD), sold over $1 million worth of Class A Ordinary Shares during late May 2026. This insider activity was reported alongside mixed financial results for the company's first quarter of 2026. While Erez's transactions were noted, other data suggests Riskified maintains a strong current ratio and received positive analyst coverage following its Q1 earnings report.

Riskified Director Sells Shares Amid Mixed Performance and Analyst Support
RSKD

Key Points

  • Director Shachar Erez sold over $1 million in Class A Ordinary Shares via an SEC filing.
  • Riskified reported Q1 2026 revenue of $88.27 million, beating expectations, despite missing EPS forecasts.
  • DA Davidson maintained a Buy rating and $6.00 price target following the release of the Q1 results.

Shachar Erez, who serves as a director at RISKIFIED LTD. (NASDAQ:RSKD), recently reported the sale of Class A Ordinary Shares through an SEC Form 4 filing. According to the regulatory document, the total value of the shares disposed of amounted to $1,044,631. These transactions were executed over a two-day period in late May.

Specifically, on May 28, 2026, Erez divested 200 Class A Ordinary Shares at an individual price point of $4.81 per share. The subsequent day, May 29, 2026, saw the sale of a significantly larger block: 216,520 Class A Ordinary Shares. These shares were sold across a range of prices, from $4.80 to $4.89, resulting in a weighted average selling price of $4.8202 per share.

It is noted that the shares disposed of were held indirectly via two entities: Qumra Capital I L.P. and Qumra Capital I Continuation Fund L.P., which are collectively referred to as Qumra Capital. Erez maintains a role as a Managing Partner within Qumra Capital, but he also formally disclaimed beneficial ownership of these specific Class A Ordinary Shares, retaining only the extent of any potential pecuniary interest.

Following these divestitures, Erez’s indirect holdings through Qumra Capital were reported to stand at 4,876,326 Class A Ordinary Shares. Furthermore, he holds an additional direct stake of 80,053 Class A Ordinary Shares, which include outstanding restricted stock units (RSUs). Regarding these directly held shares and RSUs, Erez also stated that he disclaims beneficial ownership, asserting they are held strictly for the benefit of Qumra Capital, barring any pecuniary interest.

Company Financial Health and Market Context

Despite the recent insider selling activity reported by Erez, other publicly available data suggests a robust financial position for Riskified. InvestingPro analysis indicates that the company currently holds more cash than debt and maintains a strong current ratio of 5.55.

In related news, Riskified Ltd. released its first-quarter earnings report for 2026. The results showed an earnings per share (EPS) figure of -$0.03, which fell short of the analyst consensus forecast of $0.04. However, a contrasting positive signal was provided by the revenue figures: the company’s total revenue reached $88.27 million, slightly exceeding the expected $87.9 million.

The market reaction and expert commentary also provide additional context. DA Davidson reiterated its Buy rating for Riskified, maintaining a price target of $6.00 following these results. The firm highlighted that Riskified's performance surpassed consensus expectations due to specific operational successes, namely new business wins and upselling activities. These factors contributed to an overall positive outlook from investors, suggesting that the company’s recent strategic achievements bolster confidence in its future market prospects.

Market Data Snapshot

The stock's trading data provides a snapshot of current valuation. The article notes that the stock currently trades at $5.04, and earlier price movements were also documented (e.g., 15:59:59 at USD 4.93, and an After Hours rate of 16:21:40). Additionally, the trading data suggests a recent upward trend (+0.160 or +3.28% on one recorded day).

Key Takeaways and Market Implications

  • Insider Activity: The sale of over $1 million in shares by a director, Shachar Erez, was reported via an SEC filing. This transaction involved Class A Ordinary Shares held indirectly through Qumra Capital.
  • Financial Strength vs. Earnings Miss: While the company reported an EPS shortfall (-$0.03 vs. $0.04 forecast), its revenue surpassed expectations ($88.27 million vs. $87.9 million forecast). Furthermore, the firm's liquidity remains strong, with a current ratio of 5.55 and cash exceeding debt.
  • Analyst Confidence: Following the Q1 report, DA Davidson reinforced its positive stance by reaffirming a Buy rating and setting a price target of $6.00, citing new business wins and upselling activities as key drivers.

Identified Risks and Uncertainties

  • Earnings Performance: The company missed the consensus estimate for earnings per share in Q1 2026, recording -$0.03 against a forecast of $0.04.
  • Insider Selling Pressure: The substantial sale by an executive director may suggest differing views on near-term valuation from internal stakeholders.

The sector impacted by these developments is generally the financial technology and payment processing sectors, given Riskified's operations.

Risks

  • Missing consensus estimates for earnings per share in Q1 2026 (reported -$0.03 vs. projected $0.04).
  • The significant sale of shares by an executive director, which could be interpreted as a lack of internal confidence.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026